🇺🇸 FDA
Pipeline program

Multiple Ascending Dose Study of LY4256984 in Participants with Sporadic Amyotrophic Lateral Sclerosis

J6I-MC-OWAA

Phase 1 other active

Quick answer

Multiple Ascending Dose Study of LY4256984 in Participants with Sporadic Amyotrophic Lateral Sclerosis for Sporadic Amyotrophic Lateral Sclerosis is a Phase 1 program (other) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).

Program details

Company
Eli Lilly Co.
Indication
Sporadic Amyotrophic Lateral Sclerosis
Phase
Phase 1
Modality
other
Status
active

Clinical trials